Loxo Oncology to Present at the JMP Securities Lif
Post# of 301275
STAMFORD, Conn., June 17, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 24, 2015 at 11:30AM Eastern Time.
A live webcast of the presentation will be available at http://ir.loxooncology.com/ .
About Loxo Oncology
Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential. Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. We leverage the expertise of our partners in academia and industry and our management team's deep clinical-regulatory experience to deploy focused clinical development strategies in well-defined patient populations. Our goal is to create important new cancer therapies as efficiently as possible to substantially benefit patients. www.loxooncology.com
Contacts
Loxo Oncology, Inc.
Company: Jacob S. Van Naarden Vice President, Corporate Development and Strategy jake@loxooncology.com
Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 prahmer@troutgroup.com
Media: Dan Budwick Pure Communications, Inc. 973-271-6085 dan@purecommunicationsinc.com
(0)
(0)